<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01972776</url>
  </required_header>
  <id_info>
    <org_study_id>CQBM076X2203</org_study_id>
    <secondary_id>2012-005615-92</secondary_id>
    <nct_id>NCT01972776</nct_id>
  </id_info>
  <brief_title>A Safety, Tolerability and Efficacy Study in Chronic Obstructive Pulmonary Disease (COPD) Patients With QBM076.</brief_title>
  <official_title>A Two Part, Double Blind, Placebo Controlled, Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Multiple Doses of QBM076 in Patients With COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a 2 Part study. Part 1 was a safety and tolerability study in GOLD I-III COPD
      patients. Part 2 was an efficacy study in GOLD I-III COPD patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part 1 was a double-blind, randomized, placebo-controlled, non-confirmatory study in chronic
      bronchitis COPD patients. Part 1 consisted of up to 27-days of screening period, one baseline
      period of 1 day, 13 days of bid dosing with study treatment, morning only treatment on Day
      14, follow up visits on Days 15 - 17, followed by a Study Completion evaluation. Twenty-seven
      patients were randomized in a 3:1 ratio to 3 cohorts..

      Part 2 was a double-blind, randomized, placebo-controlled, non-confirmatory study in Gold
      spirometry grades I-III COPD patients. Part 2 consisted of up to 20 days of screening period,
      a 9 day run in period, one baseline period of 1 day, 55 days of bid dosing, morning only
      dosing on Day 56, followed by Study Completion evaluation. It was planned to randomize 90
      patients in a 2:1 ratio, but part 2 was terminated after 21 patients were enrolled. Three of
      the 21 part 2 patients experienced moderate to severe (up to 17-fold) asymptomatic and
      reversible elevation of liver transaminase levels after 3 weeks of treatment with QBM076 150
      mg twice daily. Two of these patients had liver transaminase levels high enough to be
      reported as serious adverse events suspected to be related to the study drug.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Part 1 was completed. Part 2 was terminated for safety reasons.
  </why_stopped>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Adverse Events (Part 1)</measure>
    <time_frame>14 days</time_frame>
    <description>Adverse events were counted and corresponding percentages were tabulated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Lung Clearance Index (LCI) (Part 2)</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Absolute Number of Sputum Neutrophils (Part 2)</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Transition Dyspnea Index (TDI) (Part 2)</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) (Part 2)</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Time Zero to the End of the Dosing Interval, Tau (AUCtau) (Part 1)</measure>
    <time_frame>day 1 (from pre-dose to 12 hours post dose)</time_frame>
    <description>Venous blood samples were collected for concentration-time profiles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCtau, Steady State (AUCtau,ss) (Part 1)</measure>
    <time_frame>day 14 (from pre-dose to 72 hours post dose)</time_frame>
    <description>Venous blood samples were collected for concentration-time profiles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed Maximum Plasma Concentration Following Drug Administration (Cmax) (Part 1)</measure>
    <time_frame>day 1 (from pre-dose to 12 hours post dose)</time_frame>
    <description>Venous blood samples were collected for concentration-time profiles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,ss (Part 1)</measure>
    <time_frame>day 14 (from pre-dose to 72 hours post dose)</time_frame>
    <description>Venous blood samples were collected for concentration-time profiles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach the Maximum Concentration After Drug Administration (Tmax) (Part 1)</measure>
    <time_frame>day 1 (from pre-dose to 12 hours post dose)</time_frame>
    <description>Venous blood samples were collected for concentration-time profiles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax,ss (Part 1)</measure>
    <time_frame>day 14 (from pre-dose to 72 hours post dose)</time_frame>
    <description>Venous blood samples were collected for concentration-time profiles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Cluster of Differentiation 11b (CD11b) (Part 1)</measure>
    <time_frame>baseline, day 14</time_frame>
    <description>Whole blood samples were taken by either direct venipuncture or an indwelling cannula inserted in a forearm vein in order to measure CD11b expression on neutrophils. A negative change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Chemokine (C-X-C Motif) Receptor 2 (CXCR2) Receptor Occupancy (Part 1)</measure>
    <time_frame>baseline, day 14</time_frame>
    <description>Whole blood samples were taken by either direct venipuncture or an indwelling cannula inserted in a forearm vein in order to measure CXCR2 receptor occupancy on neutrophils. A positive change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Forced Expiratory Volume in One Second (FEV1) (Part 1)</measure>
    <time_frame>baseline, day 14 pre-dose</time_frame>
    <description>FEV1 is the amount of air that can be exhaled in one second. FEV1 will be measured by spirometry and performed at approximately the same time of day on each visit to avoid diurnal variation. All spirometry calibrations and evaluations followed the recommendations of the American Thoracic Society / European Respiratory Society guidelines for acceptability. A positive change from baseline in FEV1 indicates improvement in lung function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Lung Clearance Index 2.5 (LCI2.5) (Part 1)</measure>
    <time_frame>baseline, day 14 pre-dose</time_frame>
    <description>Lung clearance index (LCI) is a measure of abnormal ventilation distribution derived from the multiple breath inert gas washout (MBW) technique. LCI is equal to the cumulative expired volume/functional residual capacity. LCI was measured at baseline and day 14. LCI was analyzed using a Bayesian model for repeated measurements. The model may investigate effects for pre-dose baseline, treatment, time, age, COPD class, treatment by time interaction, and baseline by time interaction. A positive change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Forced Expirtory Flow 25-75 (FEF25-75), Forced Expiratory Volume 3 (FEV3)/Forced Vital Capacity (FVC), 1-(FEV3/FVC), FEV6, FEV1/FEV6 and Post-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) (Part 2)</measure>
    <time_frame>baseline, day 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-24 (Part 2)</measure>
    <time_frame>day 1, day 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax Between 0h and 24h (Part 2)</measure>
    <time_frame>day 1, day 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax Between 0h and 24h (Part 2)</measure>
    <time_frame>day 1, day 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Percentage Sputum Neutrophils (Part 2)</measure>
    <time_frame>baseline, day 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Diffusing Capacity of the Lung for Carbon Monoxide (DLco) (Part 2)</measure>
    <time_frame>baseline, day 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Scond/Sacin as Measured by Multiple Breath Nitrogen Washout (MBNW) (Part 2)</measure>
    <time_frame>baseline, day 56</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>QBM076 Part 1 Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received QBM076 25 mg twice daily (bid) for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>QBM076 Part 1 Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received QBM076 75 mg bid for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>QBM076 Part 1 Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received QBM076 150 mg bid for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Part 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants in each cohort received matching placebo for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>QBM076 Part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received QBM076 150 mg bid for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Part 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received matching placebo for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QBM076</intervention_name>
    <description>Supplied in 25 mg and 75 mg capsules</description>
    <arm_group_label>QBM076 Part 1 Cohort 1</arm_group_label>
    <arm_group_label>QBM076 Part 1 Cohort 2</arm_group_label>
    <arm_group_label>QBM076 Part 1 Cohort 3</arm_group_label>
    <arm_group_label>QBM076 Part 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo capsules</description>
    <arm_group_label>Placebo Part 1</arm_group_label>
    <arm_group_label>Placebo Part 2</arm_group_label>
    <other_name>Matching placebo capsules</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Part 1: Patients, smokers or ex-smokers with stable chronic bronchitis GOLD class
             I-III chronic obstructive pulmonary disease (COPD); forced expiratory volume in 1
             second ≥40% of predicted and forced expiratory volume in 1 second:forced vital
             capacity ratio ≤0.7 post bronchodilator, respectively; diffusing capacity of the lung
             for carbon monoxide ≥40%; a stable medical regimen for at least 4 weeks prior to
             screening. Current smokers can be enrolled if they currently smoke ≤1ppd for last 3
             months.

               -  Part 2: Patients, smokers or ex-smokers with GOLD spirometry class I-III COPD; a
                  stable medical regimen for at least 4 weeks prior to screening; high sensitivity
                  C reactive protein≥1.5 mg/L; forced expiratory volume in 1 second ≥30% of
                  predicted and forced expiratory volume in 1 second:forced vital capacity ratio
                  ≤0.7 post bronchodilator, respectively; with mean lung clearance index 2.5% ≥8;
                  Ex-smokers with at least 10 pack year smoking history; or current smokers with at
                  least 10 pack year smoking history who smoke ≤ 1ppd on average for last 3
                  months.; evidence of air trapping based on radiologic criteria; women of child
                  bearing potential using effective methods of contraception

        Exclusion Criteria:

          -  Part 1:Gold Class IV COPD, of moderate to significant emphysema, or evidence of
             malignancy; medication considered potential for drug drug interaction; creatinine
             clearance &lt;30ml/min; more than 1 exacerbation requiring antibiotics or oral steroids
             and/or hospitalization within 3 months of screening; women of child bearing potential
             • Part 2: Gold spirometry grade IV COPD; medication considered a potential for drug
             drug interaction; serum creatinine ≥1.9 mg/dL; more than 1 exacerbation requiring
             antibiotics or oral steroids within 2 months and/or hospitalization within 3 months of
             screening; any malignancy; evidence of severe emphysema as determined by HRCT; use of
             oral steroids, theophylline, phosphodiesterase-4 inhibitors or oral antibiotic use
             (eg.macrolides)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Grosshansdorf</city>
        <zip>22947</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bucharest</city>
        <zip>Sector 5</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9QZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Romania</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2013</study_first_submitted>
  <study_first_submitted_qc>October 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2013</study_first_posted>
  <results_first_submitted>January 22, 2016</results_first_submitted>
  <results_first_submitted_qc>February 24, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 24, 2016</results_first_posted>
  <last_update_submitted>February 24, 2016</last_update_submitted>
  <last_update_submitted_qc>February 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD, inflammation, small airways, LCI, PFTs, lung heterogeneity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>In part 1, participants were randomly assigned to one of two treatment arms in a ratio of 3:1 for each cohort. In part 2, participants were stratified by smoking status (current versus ex-smoker) and randomized in a ratio of 2:1 into one of two treatments.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>QBM076 Part 1 Cohort 1</title>
          <description>Participants received QBM076 25 mg bid for 14 days.</description>
        </group>
        <group group_id="P2">
          <title>QBM076 Part 1 Cohort 2</title>
          <description>Participants received QBM076 75 mg bid for 14 days.</description>
        </group>
        <group group_id="P3">
          <title>QBM076 Part 1 Cohort 3</title>
          <description>Participants received QBM076 150 mg bid for 14 days.</description>
        </group>
        <group group_id="P4">
          <title>Placebo Part 1</title>
          <description>Participants in each cohort received matching placebo bid for 14 days.</description>
        </group>
        <group group_id="P5">
          <title>QBM076 Part 2</title>
          <description>Participants received QBM076 150 mg bid for 8 weeks.</description>
        </group>
        <group group_id="P6">
          <title>Placebo Part 2</title>
          <description>Participants received matching placebo bid for 8 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="14"/>
                <participants group_id="P6" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="13"/>
                <participants group_id="P6" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative problems</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>QBM076 Part 1 Cohort 1</title>
          <description>Participants received QBM076 25 mg bid for 14 days.</description>
        </group>
        <group group_id="B2">
          <title>QBM076 Part 1 Cohort 2</title>
          <description>Participants received QBM076 75 mg bid for 14 days.</description>
        </group>
        <group group_id="B3">
          <title>QBM076 Part 1 Cohort 3</title>
          <description>Participants received QBM076 150 mg bid for 14 days.</description>
        </group>
        <group group_id="B4">
          <title>Placebo Part 1</title>
          <description>Participants in each cohort received matching placebo bid for 14 days.</description>
        </group>
        <group group_id="B5">
          <title>QBM076 Part 2</title>
          <description>Participants received QBM076 150 mg bid for 8 weeks.</description>
        </group>
        <group group_id="B6">
          <title>Placebo Part 2</title>
          <description>Participants received matching placebo bid for 8 weeks.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="7"/>
            <count group_id="B5" value="14"/>
            <count group_id="B6" value="7"/>
            <count group_id="B7" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" spread="5.6"/>
                    <measurement group_id="B2" value="64" spread="7.5"/>
                    <measurement group_id="B3" value="65" spread="4.5"/>
                    <measurement group_id="B4" value="61" spread="2.9"/>
                    <measurement group_id="B5" value="64" spread="5.5"/>
                    <measurement group_id="B6" value="66" spread="5.6"/>
                    <measurement group_id="B7" value="64" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Adverse Events (Part 1)</title>
        <description>Adverse events were counted and corresponding percentages were tabulated.</description>
        <time_frame>14 days</time_frame>
        <population>All randomized part 1 participants</population>
        <group_list>
          <group group_id="O1">
            <title>QBM076 Part 1 Cohort 1</title>
            <description>Participants received QBM076 25 mg bid for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>QBM076 Part 1 Cohort 2</title>
            <description>Participants received QBM076 75 mg bid for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>QBM076 Part 1 Cohort 3</title>
            <description>Participants received QBM076 150 mg bid for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Part 1</title>
            <description>Participants in each cohort received matching placebo bid for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Adverse Events (Part 1)</title>
          <description>Adverse events were counted and corresponding percentages were tabulated.</description>
          <population>All randomized part 1 participants</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="63"/>
                    <measurement group_id="O4" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Lung Clearance Index (LCI) (Part 2)</title>
        <time_frame>Baseline, 8 weeks</time_frame>
        <population>Part 2 was terminated early. Therefore, primary and secondary outcomes for part 2 were not assessed.</population>
        <group_list>
          <group group_id="O1">
            <title>QBM076 Part 2</title>
            <description>Participants received QBM076 150 mg bid for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Part 2</title>
            <description>Participants received matching placebo bid for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Lung Clearance Index (LCI) (Part 2)</title>
          <population>Part 2 was terminated early. Therefore, primary and secondary outcomes for part 2 were not assessed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Absolute Number of Sputum Neutrophils (Part 2)</title>
        <time_frame>Baseline, 8 weeks</time_frame>
        <population>Part 2 was terminated early. Therefore, primary and secondary outcomes for part 2 were not assessed.</population>
        <group_list>
          <group group_id="O1">
            <title>QBM076 Part 2</title>
            <description>Participants received QBM076 150 mg bid for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Part 2</title>
            <description>Participants received matching placebo bid for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Absolute Number of Sputum Neutrophils (Part 2)</title>
          <population>Part 2 was terminated early. Therefore, primary and secondary outcomes for part 2 were not assessed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Transition Dyspnea Index (TDI) (Part 2)</title>
        <time_frame>Baseline, 8 weeks</time_frame>
        <population>Part 2 was terminated early. Therefore, primary and secondary outcomes for part 2 were not assessed.</population>
        <group_list>
          <group group_id="O1">
            <title>QBM076 Part 2</title>
            <description>Participants received QBM076 150 mg bid for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Part 2</title>
            <description>Participants received matching placebo bid for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Transition Dyspnea Index (TDI) (Part 2)</title>
          <population>Part 2 was terminated early. Therefore, primary and secondary outcomes for part 2 were not assessed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) (Part 2)</title>
        <time_frame>Baseline, 8 weeks</time_frame>
        <population>Part 2 was terminated early. Therefore, primary and secondary outcomes for part 2 were not assessed.</population>
        <group_list>
          <group group_id="O1">
            <title>QBM076 Part 2</title>
            <description>Participants received QBM076 150 mg bid for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Part 2</title>
            <description>Participants received matching placebo bid for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) (Part 2)</title>
          <population>Part 2 was terminated early. Therefore, primary and secondary outcomes for part 2 were not assessed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-time Curve From Time Zero to the End of the Dosing Interval, Tau (AUCtau) (Part 1)</title>
        <description>Venous blood samples were collected for concentration-time profiles.</description>
        <time_frame>day 1 (from pre-dose to 12 hours post dose)</time_frame>
        <population>All Part 1 participants who received active treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>QBM076 Part 1 Cohort 1</title>
            <description>Participants received QBM076 25 mg bid for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>QBM076 Part 1 Cohort 2</title>
            <description>Participants received QBM076 75 mg bid for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>QBM076 Part 1 Cohort 3</title>
            <description>Participants received QBM076 150 mg bid for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From Time Zero to the End of the Dosing Interval, Tau (AUCtau) (Part 1)</title>
          <description>Venous blood samples were collected for concentration-time profiles.</description>
          <population>All Part 1 participants who received active treatment.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="431" spread="158"/>
                    <measurement group_id="O2" value="2060" spread="829"/>
                    <measurement group_id="O3" value="7640" spread="6770"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUCtau, Steady State (AUCtau,ss) (Part 1)</title>
        <description>Venous blood samples were collected for concentration-time profiles.</description>
        <time_frame>day 14 (from pre-dose to 72 hours post dose)</time_frame>
        <population>All Part 1 participants who received active treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>QBM076 Part 1 Cohort 1</title>
            <description>Participants received QBM076 25 mg bid for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>QBM076 Part 1 Cohort 2</title>
            <description>Participants received QBM076 75 mg bid for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>QBM076 Part 1 Cohort 3</title>
            <description>Participants received QBM076 150 mg bid for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>AUCtau, Steady State (AUCtau,ss) (Part 1)</title>
          <description>Venous blood samples were collected for concentration-time profiles.</description>
          <population>All Part 1 participants who received active treatment.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="601" spread="112"/>
                    <measurement group_id="O2" value="2220" spread="787"/>
                    <measurement group_id="O3" value="6660" spread="4320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Observed Maximum Plasma Concentration Following Drug Administration (Cmax) (Part 1)</title>
        <description>Venous blood samples were collected for concentration-time profiles.</description>
        <time_frame>day 1 (from pre-dose to 12 hours post dose)</time_frame>
        <population>All Part 1 participants who received active treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>QBM076 Part 1 Cohort 1</title>
            <description>Participants received QBM076 25 mg bid for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>QBM076 Part 1 Cohort 2</title>
            <description>Participants received QBM076 75 mg bid for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>QBM076 Part 1 Cohort 3</title>
            <description>Participants received QBM076 150 mg bid for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Observed Maximum Plasma Concentration Following Drug Administration (Cmax) (Part 1)</title>
          <description>Venous blood samples were collected for concentration-time profiles.</description>
          <population>All Part 1 participants who received active treatment.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.5" spread="28.8"/>
                    <measurement group_id="O2" value="366" spread="192"/>
                    <measurement group_id="O3" value="1810" spread="1790"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax,ss (Part 1)</title>
        <description>Venous blood samples were collected for concentration-time profiles.</description>
        <time_frame>day 14 (from pre-dose to 72 hours post dose)</time_frame>
        <population>All Part 1 participants who received active treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>QBM076 Part 1 Cohort 1</title>
            <description>Participants received QBM076 25 mg bid for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>QBM076 Part 1 Cohort 2</title>
            <description>Participants received QBM076 75 mg bid for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>QBM076 Part 1 Cohort 3</title>
            <description>Participants received QBM076 150 mg bid for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax,ss (Part 1)</title>
          <description>Venous blood samples were collected for concentration-time profiles.</description>
          <population>All Part 1 participants who received active treatment.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.0" spread="13.9"/>
                    <measurement group_id="O2" value="338" spread="123"/>
                    <measurement group_id="O3" value="2380" spread="2680"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach the Maximum Concentration After Drug Administration (Tmax) (Part 1)</title>
        <description>Venous blood samples were collected for concentration-time profiles.</description>
        <time_frame>day 1 (from pre-dose to 12 hours post dose)</time_frame>
        <population>All Part 1 participants who received active treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>QBM076 Part 1 Cohort 1</title>
            <description>Participants received QBM076 25 mg bid for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>QBM076 Part 1 Cohort 2</title>
            <description>Participants received QBM076 75 mg bid for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>QBM076 Part 1 Cohort 3</title>
            <description>Participants received QBM076 150 mg bid for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach the Maximum Concentration After Drug Administration (Tmax) (Part 1)</title>
          <description>Venous blood samples were collected for concentration-time profiles.</description>
          <population>All Part 1 participants who received active treatment.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.05" lower_limit="2.00" upper_limit="6.00"/>
                    <measurement group_id="O2" value="3.01" lower_limit="2.00" upper_limit="8.00"/>
                    <measurement group_id="O3" value="3.04" lower_limit="2.02" upper_limit="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax,ss (Part 1)</title>
        <description>Venous blood samples were collected for concentration-time profiles.</description>
        <time_frame>day 14 (from pre-dose to 72 hours post dose)</time_frame>
        <population>All Part 1 participants who received active treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>QBM076 Part 1 Cohort 1</title>
            <description>Participants received QBM076 25 mg bid for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>QBM076 Part 1 Cohort 2</title>
            <description>Participants received QBM076 75 mg bid for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>QBM076 Part 1 Cohort 3</title>
            <description>Participants received QBM076 150 mg bid for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax,ss (Part 1)</title>
          <description>Venous blood samples were collected for concentration-time profiles.</description>
          <population>All Part 1 participants who received active treatment.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="2.00" upper_limit="4.00"/>
                    <measurement group_id="O2" value="2.00" lower_limit="2.00" upper_limit="6.02"/>
                    <measurement group_id="O3" value="2.05" lower_limit="0.50" upper_limit="6.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Cluster of Differentiation 11b (CD11b) (Part 1)</title>
        <description>Whole blood samples were taken by either direct venipuncture or an indwelling cannula inserted in a forearm vein in order to measure CD11b expression on neutrophils. A negative change from baseline indicates improvement.</description>
        <time_frame>baseline, day 14</time_frame>
        <population>All Randomized Part 1 participants were considered for the analysis but participants with both baseline and day 14 values were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>QBM076 Part 1 Cohort 1</title>
            <description>Participants received QBM076 25 mg bid for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>QBM076 Part 1 Cohort 2</title>
            <description>Participants received QBM076 75 mg bid for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>QBM076 Part 1 Cohort 3</title>
            <description>Participants received QBM076 150 mg bid for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Part 1</title>
            <description>Participants in each cohort received matching placebo bid for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Cluster of Differentiation 11b (CD11b) (Part 1)</title>
          <description>Whole blood samples were taken by either direct venipuncture or an indwelling cannula inserted in a forearm vein in order to measure CD11b expression on neutrophils. A negative change from baseline indicates improvement.</description>
          <population>All Randomized Part 1 participants were considered for the analysis but participants with both baseline and day 14 values were analyzed.</population>
          <units>percentage change</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-69"/>
                    <measurement group_id="O2" value="-89"/>
                    <measurement group_id="O3" value="-75"/>
                    <measurement group_id="O4" value="-37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Chemokine (C-X-C Motif) Receptor 2 (CXCR2) Receptor Occupancy (Part 1)</title>
        <description>Whole blood samples were taken by either direct venipuncture or an indwelling cannula inserted in a forearm vein in order to measure CXCR2 receptor occupancy on neutrophils. A positive change from baseline indicates improvement.</description>
        <time_frame>baseline, day 14</time_frame>
        <population>All Randomized Part 1 participants were considered for the analysis but participants with both baseline and day 14 values were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>QBM076 Part 1 Cohort 1</title>
            <description>Participants received QBM076 25 mg bid for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>QBM076 Part 1 Cohort 2</title>
            <description>Participants received QBM076 75 mg bid for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>QBM076 Part 1 Cohort 3</title>
            <description>Participants received QBM076 150 mg bid for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Part 1</title>
            <description>Participants in each cohort received matching placebo bid for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemokine (C-X-C Motif) Receptor 2 (CXCR2) Receptor Occupancy (Part 1)</title>
          <description>Whole blood samples were taken by either direct venipuncture or an indwelling cannula inserted in a forearm vein in order to measure CXCR2 receptor occupancy on neutrophils. A positive change from baseline indicates improvement.</description>
          <population>All Randomized Part 1 participants were considered for the analysis but participants with both baseline and day 14 values were analyzed.</population>
          <units>percent change</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="104"/>
                    <measurement group_id="O3" value="129"/>
                    <measurement group_id="O4" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Forced Expiratory Volume in One Second (FEV1) (Part 1)</title>
        <description>FEV1 is the amount of air that can be exhaled in one second. FEV1 will be measured by spirometry and performed at approximately the same time of day on each visit to avoid diurnal variation. All spirometry calibrations and evaluations followed the recommendations of the American Thoracic Society / European Respiratory Society guidelines for acceptability. A positive change from baseline in FEV1 indicates improvement in lung function.</description>
        <time_frame>baseline, day 14 pre-dose</time_frame>
        <population>All Randomized Part 1 participants were considered for the analysis but participants with both baseline and day 14 values were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>QBM076 Part 1 Cohort 1</title>
            <description>Participants received QBM076 25 mg bid for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>QBM076 Part 1 Cohort 2</title>
            <description>Participants received QBM076 75 mg bid for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>QBM076 Part 1 Cohort 3</title>
            <description>Participants received QBM076 150 mg bid for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Part 1</title>
            <description>Participants in each cohort received matching placebo bid for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Forced Expiratory Volume in One Second (FEV1) (Part 1)</title>
          <description>FEV1 is the amount of air that can be exhaled in one second. FEV1 will be measured by spirometry and performed at approximately the same time of day on each visit to avoid diurnal variation. All spirometry calibrations and evaluations followed the recommendations of the American Thoracic Society / European Respiratory Society guidelines for acceptability. A positive change from baseline in FEV1 indicates improvement in lung function.</description>
          <population>All Randomized Part 1 participants were considered for the analysis but participants with both baseline and day 14 values were analyzed.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.116" spread="0.05"/>
                    <measurement group_id="O2" value="-0.008" spread="0.05"/>
                    <measurement group_id="O3" value="0.117" spread="0.05"/>
                    <measurement group_id="O4" value="0.039" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Lung Clearance Index 2.5 (LCI2.5) (Part 1)</title>
        <description>Lung clearance index (LCI) is a measure of abnormal ventilation distribution derived from the multiple breath inert gas washout (MBW) technique. LCI is equal to the cumulative expired volume/functional residual capacity. LCI was measured at baseline and day 14. LCI was analyzed using a Bayesian model for repeated measurements. The model may investigate effects for pre-dose baseline, treatment, time, age, COPD class, treatment by time interaction, and baseline by time interaction. A positive change from baseline indicates improvement.</description>
        <time_frame>baseline, day 14 pre-dose</time_frame>
        <population>All Randomized Part 1 participants were considered for the analysis but participants with both baseline and day 14 values were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>QBM076 Part 1 Cohort 1</title>
            <description>Participants received QBM076 25 mg bid for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>QBM076 Part 1 Cohort 2</title>
            <description>Participants received QBM076 75 mg bid for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>QBM076 Part 1 Cohort 3</title>
            <description>Participants received QBM076 150 mg bid for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Part 1</title>
            <description>Participants in each cohort received matching placebo bid for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Lung Clearance Index 2.5 (LCI2.5) (Part 1)</title>
          <description>Lung clearance index (LCI) is a measure of abnormal ventilation distribution derived from the multiple breath inert gas washout (MBW) technique. LCI is equal to the cumulative expired volume/functional residual capacity. LCI was measured at baseline and day 14. LCI was analyzed using a Bayesian model for repeated measurements. The model may investigate effects for pre-dose baseline, treatment, time, age, COPD class, treatment by time interaction, and baseline by time interaction. A positive change from baseline indicates improvement.</description>
          <population>All Randomized Part 1 participants were considered for the analysis but participants with both baseline and day 14 values were analyzed.</population>
          <units>index score</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.145" spread="0.42"/>
                    <measurement group_id="O2" value="0.136" spread="0.42"/>
                    <measurement group_id="O3" value="0.660" spread="0.42"/>
                    <measurement group_id="O4" value="0.063" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Forced Expirtory Flow 25-75 (FEF25-75), Forced Expiratory Volume 3 (FEV3)/Forced Vital Capacity (FVC), 1-(FEV3/FVC), FEV6, FEV1/FEV6 and Post-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) (Part 2)</title>
        <time_frame>baseline, day 56</time_frame>
        <population>Part 2 was terminated early. Therefore, primary and secondary outcomes for part 2 were not assessed.</population>
        <group_list>
          <group group_id="O1">
            <title>QBM076 Part 2</title>
            <description>Participants received QBM076 150 mg bid for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Part 2</title>
            <description>Participants received matching placebo bid for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Forced Expirtory Flow 25-75 (FEF25-75), Forced Expiratory Volume 3 (FEV3)/Forced Vital Capacity (FVC), 1-(FEV3/FVC), FEV6, FEV1/FEV6 and Post-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) (Part 2)</title>
          <population>Part 2 was terminated early. Therefore, primary and secondary outcomes for part 2 were not assessed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-24 (Part 2)</title>
        <time_frame>day 1, day 56</time_frame>
        <population>Part 2 was terminated early. Therefore, primary and secondary outcomes for part 2 were not assessed.</population>
        <group_list>
          <group group_id="O1">
            <title>QBM076 Part 2</title>
            <description>Participants received QBM076 150 mg bid for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Part 2</title>
            <description>Participants received matching placebo bid for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-24 (Part 2)</title>
          <population>Part 2 was terminated early. Therefore, primary and secondary outcomes for part 2 were not assessed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax Between 0h and 24h (Part 2)</title>
        <time_frame>day 1, day 56</time_frame>
        <population>Part 2 was terminated early. Therefore, primary and secondary outcomes for part 2 were not assessed.</population>
        <group_list>
          <group group_id="O1">
            <title>QBM076 Part 2</title>
            <description>Participants received QBM076 150 mg bid for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Part 2</title>
            <description>Participants received matching placebo bid for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax Between 0h and 24h (Part 2)</title>
          <population>Part 2 was terminated early. Therefore, primary and secondary outcomes for part 2 were not assessed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax Between 0h and 24h (Part 2)</title>
        <time_frame>day 1, day 56</time_frame>
        <population>Part 2 was terminated early. Therefore, primary and secondary outcomes for part 2 were not assessed.</population>
        <group_list>
          <group group_id="O1">
            <title>QBM076 Part 2</title>
            <description>Participants received QBM076 150 mg bid for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Part 2</title>
            <description>Participants received matching placebo bid for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax Between 0h and 24h (Part 2)</title>
          <population>Part 2 was terminated early. Therefore, primary and secondary outcomes for part 2 were not assessed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Percentage Sputum Neutrophils (Part 2)</title>
        <time_frame>baseline, day 56</time_frame>
        <population>Part 2 was terminated early. Therefore, primary and secondary outcomes for part 2 were not assessed.</population>
        <group_list>
          <group group_id="O1">
            <title>QBM076 Part 2</title>
            <description>Participants received QBM076 150 mg bid for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Part 2</title>
            <description>Participants received matching placebo bid for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Percentage Sputum Neutrophils (Part 2)</title>
          <population>Part 2 was terminated early. Therefore, primary and secondary outcomes for part 2 were not assessed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Diffusing Capacity of the Lung for Carbon Monoxide (DLco) (Part 2)</title>
        <time_frame>baseline, day 56</time_frame>
        <population>Part 2 was terminated early. Therefore, primary and secondary outcomes for part 2 were not assessed.</population>
        <group_list>
          <group group_id="O1">
            <title>QBM076 Part 2</title>
            <description>Participants received QBM076 150 mg bid for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Part 2</title>
            <description>Participants received matching placebo bid for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Diffusing Capacity of the Lung for Carbon Monoxide (DLco) (Part 2)</title>
          <population>Part 2 was terminated early. Therefore, primary and secondary outcomes for part 2 were not assessed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Scond/Sacin as Measured by Multiple Breath Nitrogen Washout (MBNW) (Part 2)</title>
        <time_frame>baseline, day 56</time_frame>
        <population>Part 2 was terminated early. Therefore, primary and secondary outcomes for part 2 were not assessed.</population>
        <group_list>
          <group group_id="O1">
            <title>QBM076 Part 2</title>
            <description>Participants received QBM076 150 mg bid for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Part 2</title>
            <description>Participants received matching placebo bid for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Scond/Sacin as Measured by Multiple Breath Nitrogen Washout (MBNW) (Part 2)</title>
          <population>Part 2 was terminated early. Therefore, primary and secondary outcomes for part 2 were not assessed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Part 1: QBM076 B.I.D 25 mg</title>
          <description>Part 1: QBM076 B.I.D 25 mg</description>
        </group>
        <group group_id="E2">
          <title>Part 1: QBM076 B.I.D 75 mg</title>
          <description>Part 1: QBM076 B.I.D 75 mg</description>
        </group>
        <group group_id="E3">
          <title>Part 1: QBM076 B.I.D 150 mg</title>
          <description>Part 1: QBM076 B.I.D 150 mg</description>
        </group>
        <group group_id="E4">
          <title>Part 1: Placebo</title>
          <description>Part 1: Placebo</description>
        </group>
        <group group_id="E5">
          <title>Part 2: QBM076 B.I.D 150 mg</title>
          <description>Part 2: QBM076 B.I.D 150 mg</description>
        </group>
        <group group_id="E6">
          <title>Part 2:QBM076 B.I.D Placebo</title>
          <description>Part 2:QBM076 B.I.D Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Abdominal tenderness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter site eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Catheter site erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Therapeutic response unexpected</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Vessel puncture site bruise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Vessel puncture site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Eyelid injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Increased upper airway secretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Skin exfoliation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Part 2 was terminated after 21 patients were enrolled. Three of the 21 patients experienced moderate to severe (up to 17-fold) asymptomatic and reversible elevation of liver transaminase levels after 3 weeks of treatment with QBM076 150 mg bid.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

